Patent intelligence · US
US 12121571
Recombinant L-asparaginase
Recombinant L-asparaginase
Patent details — US 12121571
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 22, 2024
- Expiration
- Oct 17, 2044
- Applicant
- Jazz Pharmaceuticals Ireland Limited
- Claims
- 32
- CPC classes
- A61K, A61K38/50, A61K9/0019, A61P
Quick answer
US 12121571 (Recombinant L-asparaginase) is held by Jazz Pharmaceuticals Ireland Limited. Status: granted. Granted Oct 22, 2024. Expires Oct 17, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals Ireland Limited
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K38/50, A61K9/0019, A61P, A61P1/00, A61P35/02
More from Jazz Pharmaceuticals Ireland Limited
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 12121571?
US 12121571 (Recombinant L-asparaginase) is held by Jazz Pharmaceuticals Ireland Limited. Status: granted. Granted Oct 22, 2024. Expires Oct 17, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12121571?
Jazz Pharmaceuticals Ireland Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 12121571 expire?
Our index shows an expiration date of Oct 17, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.